These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6152317)

  • 41. Increased naloxone potency induced by pretreatment with morphine and nalbuphine in mice.
    Wong CL; Wai MK
    Clin Exp Pharmacol Physiol; 1984; 11(3):301-7. PubMed ID: 6744688
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The magnitude and duration of the analgesic effect of morphine, butorphanol, and buprenorphine in rats and mice.
    Gades NM; Danneman PJ; Wixson SK; Tolley EA
    Contemp Top Lab Anim Sci; 2000 Mar; 39(2):8-13. PubMed ID: 11487232
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine.
    Chen JC; Smith ER; Cahill M; Cohen R; Fishman JB
    Life Sci; 1993; 52(4):389-96. PubMed ID: 8093631
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Contribution of individual differences to discriminative stimulus, antinociceptive and rate-decreasing effects of opioids: importance of the drug's relative intrinsic efficacy at the mu receptor.
    Morgan D; Picker MJ
    Behav Pharmacol; 1996 May; 7(3):261-284. PubMed ID: 11224419
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Focal kappa-opioid receptor-mediated dependence and withdrawal in the nucleus paragigantocellularis.
    Sinchaisuk S; Ho IK; Rockhold RW
    Pharmacol Biochem Behav; 2002 Dec; 74(1):241-52. PubMed ID: 12376173
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The analgetic effects of an intrathecally administered partial opiate agonist, nalbuphine hydrochloride.
    Schmauss C; Doherty C; Yaksh TL
    Eur J Pharmacol; 1982 Dec; 86(1):1-7. PubMed ID: 6897635
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The mu opioid irreversible antagonist beta-funaltrexamine differentiates the discriminative stimulus effects of opioids with high and low efficacy at the mu opioid receptor.
    Morgan D; Picker MJ
    Psychopharmacology (Berl); 1998 Nov; 140(1):20-8. PubMed ID: 9862398
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ultra-low doses of naltrexone or etorphine increase morphine's antinociceptive potency and attenuate tolerance/dependence in mice.
    Shen KF; Crain SM
    Brain Res; 1997 May; 757(2):176-90. PubMed ID: 9200746
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vivo apparent pA2 analysis for naltrexone antagonism of discriminative stimulus and analgesic effects of opiate agonists in rats.
    Walker EA; Makhay MM; House JD; Young AM
    J Pharmacol Exp Ther; 1994 Nov; 271(2):959-68. PubMed ID: 7965818
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clocinnamox distinguishes opioid agonists according to relative efficacy in normal and morphine-treated rats trained to discriminate morphine.
    Walker EA; Young AM
    J Pharmacol Exp Ther; 2002 Jul; 302(1):101-10. PubMed ID: 12065706
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Butorphanol and nalbuphine: a pharmacologic comparison.
    Pallasch TJ; Gill CJ
    Oral Surg Oral Med Oral Pathol; 1985 Jan; 59(1):15-20. PubMed ID: 2983281
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antinociceptive actions of morphine and buprenorphine given intrathecally in the conscious rat.
    Bryant RM; Olley JE; Tyers MB
    Br J Pharmacol; 1983 Apr; 78(4):659-63. PubMed ID: 6687818
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Review of self-administration.
    Balster RL; Lukas SE
    Drug Alcohol Depend; 1985 Feb; 14(3-4):249-61. PubMed ID: 3888576
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of the analgesic agent tramadol in normal and arthritic rats: comparison with the effects of different opioids, including tolerance and cross-tolerance to morphine.
    Kayser V; Besson JM; Guilbaud G
    Eur J Pharmacol; 1991 Mar; 195(1):37-45. PubMed ID: 2065712
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by Mu, Kappa and Delta opioid agonists.
    Picker MJ; Benyas S; Horwitz JA; Thompson K; Mathewson C; Smith MA
    J Pharmacol Exp Ther; 1996 Dec; 279(3):1130-41. PubMed ID: 8968334
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mu- and delta-opioid receptor antagonists precipitate similar withdrawal phenomena in butorphanol and morphine dependence.
    Feng YZ; Zhang T; Tokuyama S; Zhu H; Rockhold RW; Ho IK
    Neurochem Res; 1996 Jan; 21(1):63-71. PubMed ID: 8833225
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antinociceptive profiles of mu and kappa opioid agonists in a rat tooth pulp stimulation procedure.
    Steinfels GF; Cook L
    J Pharmacol Exp Ther; 1986 Jan; 236(1):111-7. PubMed ID: 2867210
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The suppression of deprivation and antagonist-induced withdrawal in morphine-dependent rhesus monkeys.
    Gmerek DE
    Neuropeptides; 1984 Dec; 5(1-3):19-22. PubMed ID: 6099494
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of Full ยต-Opioid Receptor Agonists is not Impaired by Concomitant Buprenorphine or Mixed Opioid Agonists/Antagonists - Preclinical and Clinical Evidence.
    van Niel JC; Schneider J; Tzschentke TM
    Drug Res (Stuttg); 2016 Nov; 66(11):562-570. PubMed ID: 27504867
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antinociceptive effects of opioids following acute and chronic administration of butorphanol: influence of stimulus intensity and relative efficacy at the mu receptor.
    Smith MA; Barrett AC; Picker MJ
    Psychopharmacology (Berl); 1999 Apr; 143(3):261-9. PubMed ID: 10353428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.